Sentynl Therapeutics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
25
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
3
Sentynl Therapeutics General Information
Description
Operator of a commercial-stage biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. The company acquires, develops, and commercializes prescription therapies like Nulibry, the only approved treatment for MoCD- type A and late-stage development therapies like copper histidinate for the treatment of Menkes Disease, a rare and fatal pediatric disease, thereby enabling health professionals to prescribe medicines for fast treatment and cure.
Contact Information
Website
www.sentynl.com(Operating Subsidiary)
Corporate Office
- 420 Stevens Avenue
- Suite 200
- Solana Beach, CA 92075
- United States
Corporate Office
- 420 Stevens Avenue
- Suite 200
- Solana Beach, CA 92075
- United States
Sentynl Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sentynl Therapeutics Comparisons
Industry
Financing
Details
Sentynl Therapeutics Competitors (82)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Amicus Therapeutics | Formerly VC-backed | Princeton, NJ | ||||
| Lotus Tissue Repair | Formerly VC-backed | Cambridge, MA | ||||
| Recordati Rare Diseases | Corporation | Puteaux, France | ||||
| Kolon TissueGene | Corporation | Rockville, MD |
Sentynl Therapeutics Patents
Sentynl Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2827679-A1 | Methods for synthesizing molybdopterin precursor z derivatives | Active | 18-Feb-2011 | ||
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor z derivatives | Active | 18-Feb-2011 | ||
| US-9260462-B2 | Methods for synthesizing molybdopterin precursor z derivatives | Active | 18-Feb-2011 | ||
| CA-2827679-C | Methods for synthesizing molybdopterin precursor z derivatives | Active | 18-Feb-2011 | ||
| CA-2554461-A1 | Method for obtaining precursor z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency | Active | 29-Jan-2004 | C12P17/18 |
Sentynl Therapeutics Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Matthew Heck | Co-Founder, President, Chief Executive Officer & Board Member | |
| Michael Hercz JD | Head of Legal, Compliance, Regulatory Affairs & Quality, Chief Compliance Officer, Senior Vice President & General Counsel |
Sentynl Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Sentynl Therapeutics | Co-Founder, President, Chief Executive Officer & Board Member |
Sentynl Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sentynl Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sentynl Therapeutics Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eiger BioPharmaceuticals (Global Proprietary Rights of Zokinvy (Lonafarnib)) | 03-May-2024 | Buildings and Property | |||
| BridgeBio Pharma(Global Rights of NULIBRY ) | 04-Mar-2022 | Buildings and Property | |||
| Cyprium Therapeutics (Proprietary Rights To CUTX-101 in New York) | 24-Feb-2021 | Corporate Asset Purchase | Buildings and Property |
Sentynl Therapeutics FAQs
-
When was Sentynl Therapeutics founded?
Sentynl Therapeutics was founded in 2011.
-
Who is the founder of Sentynl Therapeutics?
Matthew Heck is the founder of Sentynl Therapeutics.
-
Who is the CEO of Sentynl Therapeutics?
Matthew Heck is the CEO of Sentynl Therapeutics.
-
Where is Sentynl Therapeutics headquartered?
Sentynl Therapeutics is headquartered in Solana Beach, CA.
-
What is the size of Sentynl Therapeutics?
Sentynl Therapeutics has 25 total employees.
-
What industry is Sentynl Therapeutics in?
Sentynl Therapeutics’s primary industry is Pharmaceuticals.
-
Is Sentynl Therapeutics a private or public company?
Sentynl Therapeutics is a Private company.
-
What is the current valuation of Sentynl Therapeutics?
The current valuation of Sentynl Therapeutics is .
-
What is Sentynl Therapeutics’s current revenue?
The current revenue for Sentynl Therapeutics is .
-
Who are Sentynl Therapeutics’s investors?
Avego Management has invested in Sentynl Therapeutics.
-
Who are Sentynl Therapeutics’s competitors?
Pfizer Pakistan, Amicus Therapeutics, Lotus Tissue Repair, Recordati Rare Diseases, and Kolon TissueGene are some of the 82 competitors of Sentynl Therapeutics.
-
When was Sentynl Therapeutics acquired?
Sentynl Therapeutics was acquired on 19-Jan-2017.
-
Who acquired Sentynl Therapeutics?
Sentynl Therapeutics was acquired by Zydus Lifesciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
